A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
Coherus Oncology, Inc.
I-Mab Biopharma US Limited
AstraZeneca
Imugene Limited
IGM Biosciences, Inc.
Tyme, Inc
Taiho Pharmaceutical Co., Ltd.
EMD Serono
AstraZeneca
Daiichi Sankyo
Eli Lilly and Company
mAbxience Research S.L.
Amgen
Galectin Therapeutics Inc.
Sanofi
Sanofi
Sanofi
Sanofi
Bayer
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
AstraZeneca
Sanofi
AstraZeneca
Sanofi
Pfizer
Mast Therapeutics, Inc.